title: Blockade of OX40/OX40 ligand to decrease cytokine messenger RNA expression in acute renal allograft rejection in vitro.
abstract: OBJECTIVE
  The aim of this study was to investigate cytokine messenger RNA (mRNA) expression by peripheral blood mononuclear cells (PBMCs) from renal recipients experiencing acute rejection by blocking OX40-OX40L interactions with recombinant human OX40-Fc fusion protein (rhOX40Fc) in vitro.
  
  
  METHODS
  PBMCs were isolated from 20 recipients experiencing acute rejection episodes (rejection group) and 20 recipients with stable graft function (stable group). Levels of Th1 (interferon [IFN]-γ) and Th2 (interleukin [IL]-4) mRNA expressions by PBMCs were measured using real-time reverse transcriptase-polymerase chain reactions.
  
  
  RESULTS
  IFN-γ mRNA expression levels were significantly higher in the rejection than the stable group (P < .05). Levels of IL-4 mRNA expression were not significantly different. Among the rejection group, rhOX40Fc reduced significantly the expression of IFN-γ and IL-4 mRNA by anti-CD3-monoclonal antibody stimulated PBMCs (P < .05, and P < .01, respectively).
  
  
  CONCLUSIONS
  Blocking of the interaction between OX40 and OX40L in vitro inhibited production of Thl and Th2 type cytokines.
authors: Department of Transplantation Surgery, Central Laboratory, Tianjin First Central Hospital, Key Lab for Critical Care Medicine of the Ministry of Health, Tianjin, China.
authors: Y-L
authors: YL
authors: Wang
authors: G
authors: G
authors: Li
authors: Y-X
authors: YX
authors: Fu
authors: H
authors: H
authors: Wang
authors: Z-Y
authors: ZY
authors: Shen
mesh_terms: D000328:Adult; D064591:Allografts; D000943:Antigens, Differentiation / Q000494:pharmacology*; D016022:Case-Control Studies; D002478:Cells, Cultured; D016207:Cytokines / Q000235:genetics*; D015536:Down-Regulation; D005260:Female; D006084:Graft Rejection / Q000235:genetics* / Q000276:immunology / Q000378:metabolism; D006801:Humans; D007141:Immunoglobulin Fc Fragments / Q000494:pharmacology*; D007371:Interferon-gamma / Q000235:genetics; D015847:Interleukin-4 / Q000235:genetics; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D053278:OX40 Ligand / Q000037:antagonists & inhibitors* / Q000378:metabolism; D011446:Prospective Studies; D012333:RNA, Messenger / Q000378:metabolism*; D053262:Receptors, OX40 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D018417:Th1 Cells / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D018418:Th2 Cells / Q000187:drug effects / Q000276:immunology / Q000378:metabolism
chemical_list: D000943:Antigens, Differentiation; D016207:Cytokines; C573415:IFNG protein, human; C508598:IL4 protein, human; D007141:Immunoglobulin Fc Fragments; D053278:OX40 Ligand; C406562:OX40Ig; D012333:RNA, Messenger; D053262:Receptors, OX40; C505716:TNFRSF4 protein, human; C089251:TNFSF4 protein, human; D015847:Interleukin-4; D007371:Interferon-gamma